Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

• Main Authors: Claudia Arndt (Author), Antje Tunger (Author), Rebekka Wehner (Author), Rebecca Rothe (Author), Eleni Kourtellari (Author), Stephanie Luttosch (Author), Katharina Hannemann (Author), Stefanie Koristka (Author), Liliana R. Loureiro (Author), Anja Feldmann (Author), Torsten Tonn (Author), Theresa Link (Author), Jan Dominik Kuhlmann (Author), Pauline Wimberger (Author), Michael Philipp Bachmann (Author), Marc Schmitz (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (Her)2-negative breast cancer in combination w...